Skip to content

The study on mechanism of olanzapine-induced appetite increase in patients

The study on mechanism of olanzapine-induced appetite increase in patients

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300071979
Enrollment
Unknown
Registered
2023-05-30
Start date
2023-06-01
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

Group of schizophrenia :None

Sponsors

Shanghai Mental Health Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: For schizophrenia patients: ? Meet the diagnosis of schizophrenia (ICD-10); ? Age 18-70; ? Having Olanzapine or other Antipsychotic drugs (Aripiprazole.Ziprasidone.Amsulpiride.Blonanserin etc) for at least 12 months (allow for combination with mood stabilizers and benzodiazepines); ?The patient and his/her guardian signed the informed consent.

Exclusion criteria

Exclusion criteria: ? Received various treatments for anorexia or binge eating in last 4 weeks; ?Pregnant or lactating women; ?Organic mental disorders and mental disorders caused by psychoactive substances and non-addictive substances; ?Other diseases affecting the mental state (such as chronic obstructive pulmonary disease, myocardial infarction, angina pectoris, stroke, painful joint disease, tumor and other serious physical diseases); ?Severe heart and kidney insufficiency and other basic diseases; ?Family history of metabolic diseases such as hypertension, diabetes and hyperlipidemia; ? Patients with non-prescribed treatment, cognitive dysfunction, contraindications to ppTMS and other impact assessments and safety assessments.

Design outcomes

Primary

MeasureTime frame
Long-interval intracortical inhibition;Activation in the prefrontal cortex;

Secondary

MeasureTime frame
Yale Food Addiction Scale;Ghrelin;Leptin;Orexin;Glucagon-Like Peptide-1;Cholecystokinin;agouti-related protein;Pro-opiomelanocortin;Tyrosine—tyrosine polypeptide;Insulin;Interleukin 1ß;Interleukin 6;Interleukin 10;Interleukin 17;Interleukin 27;Interferon a;

Countries

China

Contacts

Public ContactJianhua Chen

Shanghai Mental Health Center

jianhua.chen@smhc.org.cn+86 180 1731 1011

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026